Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

Inclusion criteria

• Inclusion Criteria:

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

• Subject must be ≥ 18 years old
• Subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in Table 1, which is prescribed to them in routine primary care.
• Subject is able and willing to take part and willing to be followed up on for 48 weeks
• Subject is able to donate saliva
• Subject has signed informed consent
• Subject meets requirement for computer access implying computer literacy as measured by active use of the patient portal or their email

Exclusion criteria

• For the investigational arm only: Previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the Focused Pharmacogenomics Panel
• Pregnant or lactating (to be verbally confirmed with the patient)
• Life expectancy estimated to be less than three months as determined by patient receiving hospice care
• Duration of index drug total treatment length is planned to be less than seven consecutive days.
• Current inpatients
• Unable to consent to the study
• Unwilling to take part
• Subject has no permanent address
• Subject has no current primary care provider
• Subject is, in the opinion of the study coordinator after discussion with participating clinician/pharmacist/investigator, not suitable to participate in the study
• Patient has a diagnosis of stage 4 or 5 chronic kidney disease (CKD) or is receiving dialysis
• Patients with advanced liver failure (stage Child-Pugh C) or a diagnosis of liver cirrhosis
• History of a liver transplant or an allogeneic hematopoietic stem cell transplant
• DNA sample collected that requires retesting in the event that DNA collected was not sufficient for testing as determined by the laboratory